Sahajanand Medical Technologies IPO
Bookbuilding IPO | ₹475.00 Cr | Listing at BSE, NSE
Closed
IPO Open
Thu, Oct 15, 2026
IPO Close
Mon, Oct 19, 2026
Price Band
₹327.00 to ₹344.00
Market Cap (Pre-IPO)
₹3,496.65 Cr
IPO Details
| IPO Date | Oct 15, 2026 to Oct 19, 2026 |
| Listing Date | Tentative: Oct 23, 2026 |
| Face Value | ₹1.00 per share |
| Price Band | ₹327.00 to ₹344.00 |
| Lot Size | 43 Shares (Minimum: ₹14,792.00) |
| Sale Type | Offer For Sale |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Issue Size | ₹475.00 Crores |
| Total Shares Offered | 13,822,116 shares |
| Fresh Issue | 13,822,116 shares |
| Offer For Sale | 13,822,116 shares |
Subscription Data
| Category | Times Subscribed |
|---|---|
| QIB | 34.70x |
| NII | 14.64x |
| RII | 3.04x |
| Total | 14.21x |
Sahajanand Medical Technologies IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | 50.00 |
| Retail Shares Offered | 35.00 |
| NII Shares Offered | 15.00 |
Sahajanand Medical Technologies IPO Lot Size
Investors can bid for a minimum of 43 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 43 | ₹14,792 |
| Retail (Max) | 13 | 559 | ₹192,296 |
| S-HNI (Min) | 14 | 602 | ₹207,088 |
| S-HNI (Max) | 67 | 2,881 | ₹991,064 |
| B-HNI (Min) | 68 | 2,924 | ₹1,005,856 |
Sahajanand Medical Technologies Financial Information (Restated Consolidated)
Sahajanand Medical Technologies Ltd.'s revenue increased by 18% and profit after tax (PAT) rose by 175% between the financial year ending with March 31, 2026 and March 31, 2025.
| Period Ended | 30 Jun 2026 | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|---|
| Assets | 1,309.00 | 1,276.43 | 1,094.90 | 970.58 |
| Total Income | 354.33 | 1,218.73 | 1,035.96 | 908.59 |
| Profit After Tax | 15.09 | 69.08 | 25.15 | -7.35 |
| EBITDA | 48.58 | 170.66 | 128.02 | 110.05 |
| NET Worth | 631.72 | 616.05 | 545.23 | 526.30 |
| Reserves and Surplus | 706.86 | 692.48 | 580.71 | 556.57 |
| Total Borrowing | 320.63 | 269.53 | 224.96 | 175.27 |
Amount in ₹ Cr
Key Performance Indicators
As of Tuesday, March 31, 2026| KPI | Values |
|---|---|
| ROE (Return on Equity) | 10.35% |
| ROCE (Return on Capital Employed) | 11.57% |
| Debt/Equity | 0.27 |
| RoNW (Return on Net Worth) | 10.60% |
| PAT Margin (Profit After Tax Margin) | 5.71% |
| EBITDA Margin | 14.10% |
| Price to Book Value | 5.48 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 6.80 | 5.94 |
| P/E (x) | 50.59 | 57.91 |
Company Overview
Sahajanand Medical Technologies Limited – Company Overview
- Incorporated in October 2001, Sahajanand Medical Technologies Limited is a medical technology company engaged in the development, manufacturing and marketing of technologically advanced medical devices, primarily focused on vascular intervention and structural heart intervention.
- Product Portfolio: The Company's products include coronary stents, coronary balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents and peripheral drug-coated balloons (DCBs).
- The Company focuses on research and development, precision manufacturing and clinically supported product innovation. Its flagship brands include Supraflex Cruz, Cocoon and Hydra, catering to different areas of interventional cardiology.
- The Company operates three manufacturing facilities, including two in India and one in Thailand, supported by two R&D centres in India and Thailand.
- As of June 30, 2026, the Company had 119 patents granted globally, 78 patent applications in the pipeline and five design registrations in India.
- The Company's products were marketed in 77 countries in Fiscal 2026 through direct, hybrid and distributor-led models, with an established market presence in India, Europe and other international markets.
- Revenue from operations increased from ₹9,016.04 million in Fiscal 2024 to ₹10,248.79 million in Fiscal 2025 and ₹12,105.04 million in Fiscal 2026.
- As of June 30, 2026, the Company had 1,605 full-time employees, 31 consultants and 707 contract-based employees.
Company Strengths
- Extensive global sales and marketing network.
- Strong research and development capabilities.
- Diversified and integrated manufacturing facilities.
- Leadership in India and key international markets.
- Proven M&A and strategic collaboration capabilities.
- Technologically advanced medical devices in high-barrier segments.
- Experienced leadership team backed by reputed institutional investors.
Sahajanand Medical Technologies IPO Peer Comparison
Sahajanand Medical Technologies peer comparison with similar listed entities. (As on March 31, 2025)| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Sahajanand Medical | 6.67 | 6.48 | 62.76 | - | 10.60 | - | - |
| Poly Medicure | 31.79 | 31.75 | 306.40 | 51.40 | 10.37 | - | - |
| Laxmi Dental | 5.27 | 5.26 | 44.27 | 36.35 | 11.91 | 4.34 | - |
Quick Info
| Sector | Healthcare |
| Exchange | BSE, NSE |
| Market Cap (Pre-IPO) | ₹3,496.65 Cr |
Important Dates
| IPO Open | Oct 15, 2026 |
| IPO Close | Oct 19, 2026 |
| Allotment Date | Oct 21, 2026 |
| Credit to Demat | Oct 22, 2026 |
| Listing Date | Tentative: Oct 23, 2026 |
Lead Manager(s)
Motilal Oswal Investment Advisors Ltd.
Registrar
Description
- IPO Type: Book build issue aggregating to ₹475.48 crores.
- Issue Structure: The issue is entirely an offer for sale of 1.38 crore shares aggregating to ₹475.48 crores.
- IPO Dates: The issue opens for subscription on October 15, 2026 and closes on October 19, 2026.
- Allotment Date: The allotment is expected to be finalized on October 21, 2026.
- Listing Details: The shares are proposed to be listed on NSE and BSE on October 23, 2026.
- Retail Investment Requirement: Minimum 1 lot (43 shares) amounting to approximately ₹14,792 at the upper price band.
- Issue Price Band: ₹327 to ₹344 per equity share.
- Lot Size: 43 shares per lot.
This IPO offers investors an opportunity to participate in the company through an offer for sale by existing shareholders.